Search tips
Search criteria 


Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
Sci Rep. 2017; 7: 10665.
Published online 2017 September 6. doi:  10.1038/s41598-017-10944-4
PMCID: PMC5587683

A fluorescence-based reporter for monitoring expression of mycobacterial cytochrome bd in response to antibacterials and during infection


Cytochrome bd is a component of the oxidative phosphorylation pathway in many Gram-positive and Gram-negative bacteria. Next to its role as a terminal oxidase in the respiratory chain this enzyme plays an important role as a survival factor in the bacterial stress response. In Mycobacterium tuberculosis and related mycobacterial strains, cytochrome bd is an important component of the defense system against antibacterial drugs. In this report we describe and evaluate an mCherry-based fluorescent reporter for detection of cytochrome bd expression in Mycobacterium marinum. Cytochrome bd was induced by mycolic acid biosynthesis inhibitors such as isoniazid and most prominently by drugs targeting oxidative phosphorylation. We observed no induction by inhibitors of protein-, DNA- or RNA-synthesis. The constructed expression reporter was suitable for monitoring mycobacterial cytochrome bd expression during mouse macrophage infection and in a zebrafish embryo infection model when using Mycobacterium marinum. Interestingly, in both these infection models cytochrome bd levels were considerably higher than during in vitro culturing of M. marinum. The expression reporter described here can be a valuable tool for elucidating the role of cytochrome bd as a survival factor.


In the oxidative phosphorylation pathway the respiratory chain transfers electrons derived from NADH or other reduced shuttle molecules onto oxygen. Coupling redox reactions to proton transport, the respiratory chain complexes establish a proton motive force across a biomembrane, which is subsequently utilized by ATP synthase for synthesis of ATP. The terminal oxidases catalyze the final step in the respiratory chain, the reduction of molecular oxygen. Cytochrome bd is such a terminal oxidase and is found in many prokaryotes1. Although cytochrome bd can contribute to the proton motive force, it is energetically less efficient than other terminal oxidases, such as cytochrome bo or cytochrome aa 3-type oxidases1. Therefore, cytochrome bd typically becomes important under conditions that limit the function of these other terminal oxidases. For instance, cytochrome bd is required for respiration under low oxygen tension2 and in the presence of nitric oxide35, peroxynitrite6, and hydrogen sulfide7 in Escherichia coli. Moreover, E. coli cytochrome bd plays a central role in the defense against hydrogen peroxide8 and is strongly induced upon genetic knock-out of ATP synthase9. As such, cytochrome bd can be regarded as an important component of the bacterial stress response8.

In mycobacteria, cytochrome bd is found among both fast-growing as well as slow-growing strains. Mycobacterium tuberculosis employs a branched respiratory chain, one branch comprises the cytochrome bc 1 complex together with a cytochrome aa 3-type terminal oxidase, while the other branch employs cytochrome bd as terminal oxidase10. In M. tuberculosis and related mycobacterial strains a knock-out of cytochrome bd does not influence growth under standard growth conditions1113. However, mycobacterial cytochrome bd is upregulated under hypoxia9, in the presence of nitric oxide14 and during the transition from replicating state to non-replicating persistence14. Mycobacterial cytochrome bd is also important when the parallel cytochrome bc 1 respiratory chain branch is inactivated1518. In recent years, it has become clear that mycobacterial cytochrome bd also plays an important role in survival in the presence of antibiotics. Transcriptional and proteomic studies have revealed that cytochrome bd was strongly induced by the ATP synthase inhibitor bedaquiline in M. tuberculosis 19, and in Mycobacterium smegmatis 20. Interestingly, M. tuberculosis strains lacking cytochrome bd displayed enhanced sensitivity for bedaquiline12 and cytochrome bc 1 inhibitors17, 21, 22. A cytochrome bd knock-out in M. smegmatis was found hypersensitive for bedaquiline13, 20 and for the type-II NADH dehydrogenase effector clofazimine13. Clofazimine also induced cytochrome bd transcription in M. tuberculosis 23. These results identified cytochrome bd as an important survival factor in the presence of antibiotics and indicate that this enzyme can be an efficient drug target.

To gain insight into the role of cytochrome bd as a survival factor it is important to assess which antibacterial drugs and other stressors trigger induction of cytochrome bd. To this end, reliable molecular markers are required that are easy to handle and provide information on cytochrome bd expression in real-time. Previously, genetic reporters to monitor the expression of the iniBAC operon have been constructed and used for characterization of the mycobacterial cell wall stress response upon treatment with ethambutol and isoniazid24. These transcriptional fusions of a promoter and a gene encoding a fluorescent reporter proved to be successful in following operon induction kinetics as well as assessment of the mode of action of new drugs (M. Boot et al., in preparation). In this study we employ this approach and construct a molecular reporter as a tool for monitoring mycobacterial cytochrome bd gene expression in response to antibacterial compounds and during infection.


Construction of the cytochrome bd expression reporter

The cytochrome bd terminal oxidase consists of two main subunits, CydA (subunit I) and CydB (subunit II)25, 26. Although the presence of a third, minor subunit has been demonstrated for cytochrome bd in various bacterial strains such as E. coli.27, 28 and Geobacillus thermodenitrificans 29 our database search indicated no homologues of these minor subunits in the mycobacterial genome. In mycobacteria, the cydA and cydB genes are located in one operon under control of the cyclic AMP receptor protein30. To construct the cytochrome bd expression reporter we amplified the region containing the cydA promoter (MMAR_2426) from Mycobacterium marinum MUSA. To visualize operon induction, we placed the gene encoding the fluorescent protein mCherry under the control of this promoter (Fig. 1A).

Figure 1
Construction and basic characterization of the cytochrome bd expression reporter. (A) Genetic construction of the reporter plasmid with the mCherry gene under control of the cydA promoter. (B) Growth of Mycobacterium marinum carrying the cydA reporter ...

For our study we used M. marinum, a slow-growing, pathogenic mycobacterium that is genetically closely related to strains of the M. tuberculosis complex31. Moreover, M. marinum can be used in combination with the zebrafish embryo infection model, a powerful in vivo tool that has been shown to mimic the infection processes of M. tuberculosis accurately32, 33, and can be used for anti-mycobacterial drug discovery34.

Construction and basic characterization of the cydA expression reporter

M. marinum carrying the plasmid encoding mCherry under control of the cydA promoter, referred to as the cydA reporter strain, displayed similar growth characteristics as the parent strain (‘wild-type’) (Fig. 1B). We confirmed that the cydA reporter strain emitted substantially higher fluorescence than the wild-type control during three days of culture and subsequently deducted the auto-fluorescence of the WT control from induction levels observed in flow cytometry experiments. Next, we assessed the induction of the reporter under normoxia and hypoxia (Fig. 1C). Under normoxia, the observed fluorescence was stable and did not increase over the course of the experiment. When cultured under low oxygen tension, we observed a small cydA induction over time (Fig. 1C). In the presence of the nitric oxide donor DETA-NO, previously found to enhance cydA transcripts in M. tuberculosis 14, we observed cydA induction at concentrations of 1x MIC (125 uM) and 10x MIC (Fig. 1D). These results indicate that the cydA reporter is functional.

Selected antibacterials in the M. marinum/zebrafish embryo infection model

In order to evaluate which type of drugs trigger expression of cytochrome bd we first confirmed that selected antibacterials were active against M. marinum. Both front-line drugs as well as experimental drugs with various mechanisms of action were tested, including three drugs targeting oxidative phosphorylation (Table 1). The latter included the ATP synthase inhibitor bedaquiline (BDQ)3537, the cytochrome bc 1 inhibitor Q20338 and the type-II NADH dehydrogenase effector clofazimine (CFZ)39. BDQ has been approved for treatment of multi-drug resistant tuberculosis, Q203 presently is evaluated in phase I clinical trials, and clofazimine is already in clinical use for treatment of leprosy and presently is being re-purposed as anti-TB drug.

Table 1
List of antibiotics and minimal inhibitory concentrations (MICs) used in this study.

We determined the minimal inhibitory concentrations (Table 1) and also characterized BDQ, Q203 and CFZ activity against M. marinum in a zebrafish embryo infection model. The zebrafish embryo infection model allows for real-time visualization of fluorescently labeled pathogens40, 41. The colonization of zebrafish embryos by M. marinum is visualized by a constitutively expressed mEos3.1 variant and can be quantified by fluorescence microscopy40, 42 (Fig. 2A). BDQ prevented bacterial colonization in a dose-dependent manner (Fig. 2B). Q203 also suppressed bacterial growth at 1x MIC, however, at 5x MIC and 10x MIC the compound seemed to precipitate, apparently limiting its activity (Fig. 2C). At 1x MIC, CFZ cleared bacterial loads, whereas concentrations of 5x MIC and higher were toxic for the zebrafish embryo host under these conditions (Fig. 2D). These results show that BDQ, Q203 and CFZ are active against M. marinum.

Figure 2
Selected drugs are active in a zebrafish embryo infection model 3 days post treatment. (A) Infected fish, untreated (top) brightfield and fluorescence image as compared to a control, uninfected fish. (B) BDQ treated fish. (C) Treatment ...

Cytochrome bd induction by antibacterial compounds

Ethambutol and isoniazid, both inhibitors of mycobacterial cell envelope biosynthesis43, 44, showed slight cydA induction when high concentrations were applied (10x MIC) (Fig. 3). In contrast, the RNA polymerase inhibitor rifampicin decreased cydA expression at 10x MIC as compared to control samples (Fig. 3). Among the second-line drugs used for tuberculosis treatment, pronounced cydA downregulation was observed for the protein synthesis inhibitor streptomycin at 10x MIC (Fig. 3), and for the DNA gyrase inhibitor ciprofloxacin at 10x MIC (Fig. 3). Next, we tested drugs active on three distinct targets in the oxidative phosphorylation pathway. As depicted in Fig. 4, all three drugs, BDQ, CFZ and Q203, significantly induced cytochrome bd expression at 1x MIC and 10x MIC (Fig. 3). These data reveal that inhibitors with different mechanisms of action can induce cydA expression, but induction was most prominent in response to inhibitors of oxidative phosphorylation. We confirmed the validity of the cydA reporter by quantitative reverse-transcription PCR, which clearly showed increased levels of cydA transcripts in the presence of inhibitors of oxidative phosphorylation (Supplementary Figure 1). As these three drugs are slow-acting and display only minimal kill of M. tuberculosis in the first 2–3 days of treatment19, 38, 45, we subsequently investigated time- and concentration dependency of cydA expression in more detail for these drugs.

Figure 3
Differential regulation of cydA in response to antibacterials analyzed by flow cytometry. A histogram plot showing the number of events (y-axis). Peak height indicates mCherry fluorescence intensity (x-axis) for: Untreated samples (red line), ...
Figure 4
Time- and concentration dependency of cydA induction by inhibitors of oxidative phosphorylation. (A) Response to BDQ for 1x, 10x and 100x MIC over time. (B) Response to Q203 for 1x, 10x and 15x MIC. (C) Response to CFZ for 1x, 10x and 60x MIC. The fold ...

Time- and concentration dependency of cydA induction

For the ATP synthase inhibitor BDQ, cytochrome bd induction increased from 2.3 fold at day 1 to 4.5-fold at day 2 of treatment, with only marginal changes between day 2 and day 3 time points (Fig. 4A). For this drug, maximal induction was achieved at 1x MIC and induction dropped at elevated concentrations (10x MIC and 100x MIC) at all three time points investigated (Fig. 4A). For the cytochrome bc 1 inhibitor Q203 cydA induction levels at 1x MIC induction steadily increased to 8.3-fold at day 3 (Fig. 4B). Similar to BDQ, induction by Q203 at 1x MIC was stronger as compared to higher drug concentrations at all three time points (Fig. 4B). The NDH-2 effector CFZ at 1x MIC triggered slowly increasing cydA levels until day 3 (Fig. 4C). CFZ displayed only marginal concentration-dependency of induction at day 1 and day 2, whereas at day 3 induction was clearly higher at 10x MIC (6.6-fold) and 60x MIC (6.9-fold (Fig. 4C). For comparison, the time- and concentration dependency of cydA regulation by the front-line drugs are shown in Supplementary Figure 2.

In line with the delayed bactericidal activity of the three oxidative phosphorylation inhibitors induction of cytochrome bd was time-dependent and maximal induction was not reached before two days of treatment. Both BDQ and Q203 showed maximal cytochrome bd expression at concentrations of 1x MIC, whereas the higher, bactericidal concentrations were less effective in cytochrome bd induction. These two inhibitors strongly decrease bacterial ATP levels19, 36, 38. It can be speculated that pronounced ATP depletion at elevated drug concentrations renders the bacteria less capable of mobilizing an effective metabolic response.

The cydA reporter induced in macrophages

To evaluate if cytochrome bd expression can be monitored under conditions as encountered within a mammalian host we examined the cydA reporter in a mouse macrophage infection model. To differentiate between infected and non-infected macrophages and to assess which proportion of the infected cells expressed the cydA reporter, we introduced an integrative plasmid with a gene encoding fluorescent protein mEos3.1 under control of the hsp60 promoter in our M. marinum cydA reporter strain. Expression levels of mCherry (cydA) and mEos3.1 were assessed by flow cytometry using a gating strategy depicted in Supplementary Figure 3. The analysis showed that the percentage of untreated mEos3.1-positive RAW macrophage cells steadily increased within a 3-day period after start of infection (Fig. 5A). Treatment with BDQ suppressed infection (Fig. 5A). To assess cydA expression relative to bacterial cell number, we normalized the mCherry signal relative to the mEos3.1 signal. Whereas for M. marinum in culture the mCherry signal was ~70fold lower than the mEos3.1 signal, during RAW cell infection the ratio mCherry/mEos3.1 ratio increased to ~1:3 within one day. Prolonged incubation resulted in a marginal further increase between day 1 and day 3 of infection (Fig. 5B). Upon treatment with BDQ an additional increase of the normalized cydA expression in the RAW cell infection model was observed (Fig. 5C). These results suggest that the cydA reporter is working in a mouse cell line infection model and that cytochrome bd is induced during intracellular growth.

Figure 5
The cydA reporter in a mouse macrophage infection model. (A) The percentage of infected RAW cells over time for NT (non-treated) as compared to cells that were treated with 1x or 10x MIC BDQ. The experiment was performed in triplicate and error bars represent ...

The cydA reporter is functional in a vertebrate host system

Next, we explored if the constructed cydA reporter can also be used to study cytochrome bd expression in a zebrafish embryo infection model. M. marinum carrying the cydA reporter and the constitutive mEos3.1 marker were injected into in the hindbrain ventricle of zebrafish embryos. Both mCherry and mEos3.1 fluorescence signals were readily detectable by confocal microcopy. The mEos3.1 signal allowed for monitoring the spread of the infection within the hindbrain (Fig. 6, upper row). Treatment with BDQ decreased bacterial growth (Supplementary Figure 4), supporting the usage of a hindbrain ventricle infection model to address drug efficacy. Although quantification of in vivo fluorescent signals is difficult, a similar trend was observed for the mCherry signal as in the macrophage infection model. Even without antibiotic treatment high induction of the mCherry reporter was visible in vivo, exceptionally pronounced at day 4 post infection (Fig. 6, middle and lower row). Due to the high cydA expression levels in the non-treated control we were not able to quantify if treatment with BDQ additionally induced cydA (Supplementary Figure 4). Interestingly, in certain infected areas of the central nervous system mCherry induction appeared exceptionally strong (Fig. 6, lower row), which may be due to varying levels of cytochrome bd inducing factors in specific micro-environments. These results show that the cydA reporter allows for monitoring cytochrome bd expression in vivo and indicates that cytochrome bd is produced at elevated levels during infection in a vertebrate host.

Figure 6
The cydA reporter in a zebrafish embryo model. Confocal microscopy images of casper zebrafish embryos at maximum projection. Time course of mEos3.1 and mCherry signals during infection (dpi = days post infection). Upper row: mEos3.1 signal ...


Previously, alkaline phosphatase fusions to subunit I or subunit II have been applied to investigate cytochrome bd topology46 and a galactosidase-based marker was used to assess cytochrome bd expression under hypoxia11. Green Fluorescent Protein (GFP)-fusions to subunit II facilitated investigation of cytochrome bd dynamics in the E. coli cytoplasmic membrane47 and in Corynebacterium glutamicum GFP under the control of the cytochrome bd promoter was used to study expressional control of the branched respiratory chain48. In our study, we describe an expression reporter for cytochrome bd in a pathogenic (myco)bacterium. M. marinum, and we applied this reporter to evaluate differential regulation of cytochrome bd in response to antibiotics and during infection. The marker revealed cytochrome bd induction in response to antibacterials of different classes, but in particular to inhibitors of oxidative phosphorylation. Drugs targeting this pathway are under consideration as components for next-generation anti-tuberculosis chemotherapy regimen4952. The reporter constructed here may assist in characterizing new candidate antibacterials and may provide input for the rational combination of antibacterials in drug regimen. It would be interesting to test if induction of cytochrome bd in response to inhibition of oxidative phosphorylation is also found in non-mycobacterial pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae or Acinetobacter baumanii, for which small molecules targeting ATP synthase and components of the respiratory chain have been reported previously5355.

Induction of cytochrome bd in response to clofazimine, a ROS-producing drug39, is most likely due to this enzyme’s ability to metabolize and/or prevent the formation of peroxides. Cytochrome bd as a high-affinity oxygen scavenger2 may decrease the intracellular oxygen tension, thereby preventing the formation of reactive oxygen species. Moreover, for cytochrome bd from E. coli both catalase activity56 and peroxidase activity57 has been reported. This enzyme may thus directly metabolize peroxides. Activity of BDQ and Q203 was not found linked to ROS production13, 18. Induction of cytochrome bd may facilitate respiratory electron flow when the cytochrome bc 1 complex is inhibited by Q203. Enhanced levels of cytochrome bd in response to the ATP synthase inhibitor BDQ may prevent membrane hyperpolarization and/or maintain respiratory electron flow. Alternatively, cytochrome bd induction may be associated with the enhanced respiratory flux and the uncoupling effect reported for bactericidal concentrations of BDQ20, 58.

The cydA reporter revealed high cytochrome bd levels for M. marinum in two relevant infection models, illustrating the importance of this respiratory protein for survival in the host. In a recent report no clear attenuation phenotype was found for a ΔcydAB strain in mice22, however, consistent with our findings, earlier results indicated that genetic inactivation of cytochrome bd in M. tuberculosis decreased bacterial counts in a mouse infection model14. In addition, numerous studies suggest that lack of a functional cytochrome bd severely compromises bacterial viability during infection for a broad spectrum of Gram-positive and Gram-negative bacterial strains, such as Group B Streptococcus 59, Staphylococcus aureus 60, Shigella flexneri 61, Brucella abortus 62, Salmonella enterica 63, 64 and uropathogenic E. coli strains65. It needs to be clarified to which extent elevated cytochrome bd levels represent a general feature of pathogens residing in a vertebrate host. Fluorescent expression reporters, such as constructed and characterized here, may be important tools for elucidating the role of cytochrome bd in pathogenic bacteria.

Materials and Methods

Construction of the cydA reporter plasmid

A list of primers can be found in supplemental Table 1. Anchored primers containing either an XbaI site or BamHI site were used to amplify a 290-bp fragment that included the cydA promoter from M. marinum MUSA genomic DNA. Subsequently, both the pAL5000 plasmid derivative pSMT3-iniB-mCherry24 and the amplified PCR product were digested with XbaI and BamHI, mixed, and ligated, resulting in pSMT3-pCydA-mCherry.

Strains and culturing conditions

M. marinum wild type MUSA 66 was used as a basis for mycobacterial experiments. Cultures were grown in Middlebrook 7H9 liquid medium supplemented with Middlebrook ADC (Difco) and 0.05% Tween 80. Antibiotics (Sigma) were added to cultures where indicated. Antibiotics for the induction experiments were routinely added to log-phase cultures at the indicated final concentrations. Middlebrook 7H10 solid agar supplemented with Middlebrook OADC was used for bacterial culturing on agar plates. Both cultures and plates were grown at 30 °C. For hypoxic conditions, M. marinum cultures were grown to log phase in a culture flask in Middlebrook 7H9 medium at 30 °C and diluted to an OD600 of 0.3 per mL. A total of 1.5 mL was incubated per screwcap tube to acquire a headspace ratio (HSR) of ~0.567. The tubes were incubated at 30 °C on a shaker. Per time point one tube was opened and the hypoxic culture was tested for growth, as measured by OD600, and expression of cydA by flow cytometry. Experiments were performed three independent times

Flow cytometry analysis

The induction of cydA was measured by flow cytometry. M. marinum containing the reporter plasmid was grown to an OD600 of 0.2–0.3, and antibiotics were added to the indicated concentrations for a specified amount of time. For each time point, 1 mL culture was collected, spun down by centrifugation, washed once with PBS containing 0.05% Tween 80 and resuspended in 100 µl 0.05% Tween 80. Cell infections were also analyzed by flow cytometry. Cell infection samples were resuspended in PBS. Samples were acquired on a BD Accuri C6 flow cytometer (BD Biosciences) equipped with a 488-nm laser and 610/20-nm filter to detect mCherry and 530/30-nm filter to detect mEos3.1. The exact gating strategy varied between experiments. Per sample, 30,000 gated events were collected per time point, and data were analyzed using BD CFlow software and GraphPad prism 6.

RNA isolation and qRT-PCR

RNA isolation was performed with a NucleoSpin® RNA kit (Machery Nagel). In total 25 OD units were spun down and used for isolation per sample. Isolation was performed with three biological replicates. There was one deviation compared to the first step of the manufacturer’s protocol to lyse the mycobacterial cells. Cells were beadbeated in 500 μL Buffer RA1 and 5 μL ß-mercaptoethanol for 1 minute. Subsequent steps were according to the protocol provided by the manufacturer. RNA samples were subsequently treated with DNAseI (Thermo Scientific) according to manufacturer’s protocol. Equal amounts of RNA were analyzed in an ABI7500 thermocycler using a EXPRESS One-Step Superscript® qRT-PCR Kit. Instructions supplied with the kit were followed. sigA was used as a reference gene for qRT-PCR. The sequences for the primers and probes can be found in Supplementary Table 1. The resulting data of triplicates were analyzed using the ABI7500 software.

Cell infection assay with RAW macrophages

For RAW cell infection, 2 × 104 cells per well were seeded in 12 wells plates (Corning) and grown for 4 days until ~70% confluence. The cydA reporter strain that also contained the integrated pMV-hsp60-mEos3.1 was grown to an OD600 of 0.8–1.5 and washed with DMEM + FBS (10%) prior to infection. Bacterial cells were subsequently added to a multiplicity of infection of 2. RAW cells were incubated at 33 °C After three hours, extracellular mycobacteria were removed by washing 2 times with PBS. Amikacin was added to a final concentration of 200 μg/mL for 3 hours to kill any remaining extracellular mycobacterial cells. Cell were then washed and BDQ was added at the indicated concentrations. At time points 24 hpi, 48 hpi, and 72 hpi RAW cells were harvested by addition of trypsine (Sigma). The trypsin was neutralized by addition of DMEM + FBS (10%) and cells were pelleted at 1400 rpm. Cells were subsequently fixated with 4% PFA for 30 minutes at room temperature, washed with PBS and analyzed by flow cytometry.

Infection of zebrafish embryos

To assess the antimycobacterial effect of Q203, clofazimine and BDQ, zebrafish embryos were infected with 100 colony forming units (CFUs) in the caudal vein by microinjection with M. marinum MUSA containing the plasmid pSMT3-hsp60-mEos3.1. (Stoop et al./van Leeuwen et al. unpublished). The embryos were treated 1 day post infection with the aforementioned antibiotics at the indicated concentrations. Fluorescence was monitored at specific time-points with a Leica MZ16FA fluorescence microscope and a Leica DFC420C camera. All experiments were performed at least three times. For expression analysis in zebrafish embryos pMV-hsp60-mEos3.1 68 was introduced in M. marinum MUSA already containing the cydA reporter plasmid. Zebrafish embryos were injected with 2000 CFUs by microinjection in the hindbrain ventricle, as previously described24, 41. Subsequently, zebrafish embryos were fixated O/N at 0, 2 and 4 days post infection in 4% paraformaldehyde dissolved in PBS, washed with PBS and subsequently stored in PBS at 4 °C. For confocal microscopy, zebrafish were mounted in 1% low-melting-point agarose in PBS and imaged with a Leica TCS SP8 confocal microscope.

Animal experiments

All methods were carried out in accordance with relevant guidelines and regulations. Danio rerio (zebrafish) were handled in compliance with the local animal welfare regulations and maintained according to standard protocols ( The breeding of adult fish was approved by the local animal welfare committee (Animal Experimental licensing Committee, DEC) of the VU University medical center. All protocols adhered to the international guidelines specified by the EU Animal Protection Directive 86/609/EEC, which allows zebrafish embryos to be used up to the moment of free-living (approximately 5–7 days after fertilization). Because embryos used in this study met these criteria, this specific study was therefore approved by the Animal Experimental Licensing Committee of the VU University medical center (Amsterdam, the Netherlands).

Data availability

All data generated or analysed during this study are included in this published article or its Supplementary Information files.

Electronic supplementary material


The research leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115337, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contribution. The grant was awarded to Wilbert Bitter. The authors wish to thank Christina Vandenbroucke-Grauls, Astrid van der Sar for helpful discussions and Anneke Johnson and Henk Hakvoort for technical assistance.

Author Contributions

Author Contributions

M.B., K.K.J., S.C., W.B., H.L. and D.B. designed experiments and analyzed data. M.B., K.K.J., S.C., T.V., T.L. and P.L. performed experiments; D.B. and W.B. supervised and coordinated experiments; M.B. and D.B. wrote the manuscript with contributions from all co-authors, D.B. supervised the overall research.


Competing Interests

The authors declare that they have no competing interests.


Electronic supplementary material

Supplementary information accompanies this paper at doi:10.1038/s41598-017-10944-4

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


1. Borisov VB, Gennis RB, Hemp J, Verkhovsky MI. The cytochrome bd respiratory oxygen reductases. Biochim. Biophys Acta. 2011;1807:1398–1413. doi: 10.1016/j.bbabio.2011.06.016. [PMC free article] [PubMed] [Cross Ref]
2. D’mello R, Hill S, Poole RK. The cytochrome bd quinol oxidase in Escherichia coli has an extremely high oxygen affinity and two oxygenbinding haems: implications for regulation of activity in vivo by oxygen inhibition. Microbiology. 1996;142:755–763. doi: 10.1099/00221287-142-4-755. [PubMed] [Cross Ref]
3. Borisov VB, et al. Interaction of the bacterial terminal oxidase cytochrome bd with nitric oxide. FEBS Lett. 2004;576:201–220. doi: 10.1016/j.febslet.2004.09.013. [PubMed] [Cross Ref]
4. Borisov VB, et al. Redox control of fast ligand dissociation from Escherichia coli cytochrome bd. Biochem Biophys Res Commun. 2007;355:97–102. doi: 10.1016/j.bbrc.2007.01.118. [PubMed] [Cross Ref]
5. Mason MG, et al. Cytochrome bd confers nitric oxide resistance to Escherichia coli. Nat. Chem. Biol. 2009;5:94–96. doi: 10.1038/nchembio.135. [PubMed] [Cross Ref]
6. Borisov VB, Forte E, Siletsky SA, Sarti P, Giuffrè A. Cytochrome bd from Escherichia coli catalyzes peroxynitrite decomposition. Biochim Biophys Acta. 2015;1847:182–188. doi: 10.1016/j.bbabio.2014.10.006. [PubMed] [Cross Ref]
7. Forte E, et al. The Terminal Oxidase Cytochrome bd Promotes Sulfideresistant Bacterial Respiration and Growth. Sci. Rep. 2016;6 doi: 10.1038/srep23788. [PMC free article] [PubMed] [Cross Ref]
8. Wall D, et al. arc-dependent thermal regulation and extragenic suppression of the Escherichia coli cytochrome d operon. J. Bacteriol. 1992;1174:6554–6562. doi: 10.1128/jb.174.20.6554-6562.1992. [PMC free article] [PubMed] [Cross Ref]
9. Noda S, et al. Alterations of cellular physiology in Escherichia coli in response to oxidative phosphorylation impaired by defective F1-ATPase. J. Bacteriol. 2006;188:6869–6876. doi: 10.1128/JB.00452-06. [PMC free article] [PubMed] [Cross Ref]
10. Giuffre A, Borisov VB, Arese M, Sarti P, Forte E. Cytochrome bd oxidase and bacterial tolerance to oxidative and nitrosative stress. Biochim. Biophys. Acta. 2014;1837:1178–1187. doi: 10.1016/j.bbabio.2014.01.016. [PubMed] [Cross Ref]
11. Kana BD, et al. Characterization of the cydAB-encoded cytochrome bd oxidase from mycobacterium smegmatis. J. Bacteriol. 2001;183:7076–7086. doi: 10.1128/JB.183.24.7076-7086.2001. [PMC free article] [PubMed] [Cross Ref]
12. Berney M, Hartman TE, Jacobs WR., Jr. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. mBio. 2014;5:e01275–01214. doi: 10.1128/mBio.01275-14. [PMC free article] [PubMed] [Cross Ref]
13. Lu P, et al. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Scientific reports. 2015;5 doi: 10.1038/srep10333. [PMC free article] [PubMed] [Cross Ref]
14. Shi L, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl. Acad. Sci. USA. 2005;102:15629–15634. doi: 10.1073/pnas.0507850102. [PubMed] [Cross Ref]
15. Matsoso LG, et al. Function of the cytochrome bc1-aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. J. Bacteriol. 2005;187:6300–6308. doi: 10.1128/JB.187.18.6300-6308.2005. [PMC free article] [PubMed] [Cross Ref]
16. Small JL, et al. Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in mycobacterium tuberculosis. MBio. 2013;4:e00475–13. doi: 10.1128/mBio.00475-13. [PMC free article] [PubMed] [Cross Ref]
17. Arora K, et al. Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014;58:6962–6965. doi: 10.1128/AAC.03486-14. [PMC free article] [PubMed] [Cross Ref]
18. Lamprecht DA, et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat. Commun. 2016. 2016;7 [PMC free article] [PubMed]
19. Koul A, et al. Delayed bactericidal response of mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat. Commun. 2014;5 doi: 10.1038/ncomms4369. [PMC free article] [PubMed] [Cross Ref]
20. Hards K, et al. Bactericidal mode of action of bedaquiline. J. Antimicrob. Chemother. 2015;70:2028–2037. [PubMed]
21. Moraski GC, et al. Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB. ACS Infect. Dis. 2016;2:393–398. doi: 10.1021/acsinfecdis.5b00154. [PubMed] [Cross Ref]
22. Kalia, N. P. et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proc. Natl Acad Sci USA, doi:10.1073/pnas.1706139114 (2017 Jun 26). [PubMed]
23. Boshoff HI, et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 2004;279:40174–40184. doi: 10.1074/jbc.M406796200. [PubMed] [Cross Ref]
24. Boot M, et al. iniBAC induction Is Vitamin B12- and MutAB-dependent in Mycobacterium marinum. J. Biol. Chem. 2016;291:19800–12. doi: 10.1074/jbc.M116.724088. [PMC free article] [PubMed] [Cross Ref]
25. Miller MJ, Gennis RB. The purification and characterization of the cytochrome d terminal oxidase complex of the Escherichia coli aerobic respiratory chain. J. Biol. Chem. 1983;258:9159–9165. [PubMed]
26. Kita K, Konishi K, Anraku Y. Terminal oxidases of Escherichia coli aerobic respiratory chain. II. Purification and properties of cytochrome b558-d complex from cells grown with limited oxygen and evidence of branched electron-carrying systems. J. Biol. Chem. 1984;259:3375–3381. [PubMed]
27. VanOrsdel CE, et al. The Escherichia coli CydX protein is a member of the CydAB cytochrome bd oxidase complex and is required for cytochrome bd oxidase activity. J. Bacteriol. 2013;195:3640–3650. doi: 10.1128/JB.00324-13. [PMC free article] [PubMed] [Cross Ref]
28. Hoeser J, Hong S, Gehmann G, Gennis RB, Friedrich T. Subunit CydX of Escherichia coli cytochrome bd ubiquinol oxidase is essential for assembly and stability of the di-heme active site. FEBS Lett. 2014;588:1537–1541. doi: 10.1016/j.febslet.2014.03.036. [PubMed] [Cross Ref]
29. Safarian S, et al. Structure of a bd oxidase indicates similar mechanisms for membrane-integrated oxygen reductases. Science. 2016;352:583–586. doi: 10.1126/science.aaf2477. [PMC free article] [PubMed] [Cross Ref]
30. Aung HL, Berney M, Cook GM. Hypoxia-activated cytochrome bd expression in Mycobacterium smegmatis is cyclic AMP receptor protein dependent. J. Bacteriol. 2014;196:3091–3097. doi: 10.1128/JB.01771-14. [PMC free article] [PubMed] [Cross Ref]
31. Stinear TP, et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res. 2008;18:729–741. doi: 10.1101/gr.075069.107. [PubMed] [Cross Ref]
32. van der Sar AM, Appelmelk BJ, Vandenbroucke-Grauls CM, Bitter W. A star with stripes: zebrafish as an infection model. Trends Microbiol. 2004;12:451–457. doi: 10.1016/j.tim.2004.08.001. [PubMed] [Cross Ref]
33. Tobin DM, Ramakrishnan L. Comparative pathogenesis of Mycobacterium marinum and Mycobacterium tuberculosis. Cell. Microbiol. 2008;5:1027–1039. doi: 10.1111/j.1462-5822.2008.01133.x. [PubMed] [Cross Ref]
34. Takaki K, Cosma CL, Troll MA, Ramakrishnan L. An in vivo platform for rapid high-throughput antitubercular drug discovery. Cell Rep. 2012;2:175–184. doi: 10.1016/j.celrep.2012.06.008. [PMC free article] [PubMed] [Cross Ref]
35. Andries K, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–227. doi: 10.1126/science.1106753. [PubMed] [Cross Ref]
36. Koul A, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 2007;3:323–324. doi: 10.1038/nchembio884. [PubMed] [Cross Ref]
37. Haagsma AC, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One. 2011;6 doi: 10.1371/journal.pone.0023575. [PMC free article] [PubMed] [Cross Ref]
38. Pethe K, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 2013;19:1157–1160. doi: 10.1038/nm.3262. [PubMed] [Cross Ref]
39. Yano T, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 2011;286:10276–10287. doi: 10.1074/jbc.M110.200501. [PMC free article] [PubMed] [Cross Ref]
40. van der Sar AM, et al. Mycobacterium marinum strains can be divided into two distinct types based on genetic diversity and virulence. Infect. Immun. 2004;72:6306–6312. doi: 10.1128/IAI.72.11.6306-6312.2004. [PMC free article] [PubMed] [Cross Ref]
41. Jim KK, et al. Infection of zebrafish embryos with live fluorescent Streptococcus pneumoniae as a real-time pneumococcal meningitis model. J. Neuroinflammation. 2016;13 doi: 10.1186/s12974-016-0655-y. [PMC free article] [PubMed] [Cross Ref]
42. Stoop EJ, et al. Zebrafish embryo screen for mycobacterial genes involved in the initiation of granuloma formation reveals a newly identified ESX-1 component. Dis. Model. Mech. 2011;4:526–536. doi: 10.1242/dmm.006676. [PMC free article] [PubMed] [Cross Ref]
43. Belanger AE, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. USA. 1996;93:11919–11924. doi: 10.1073/pnas.93.21.11919. [PubMed] [Cross Ref]
44. Vilchèze C, Jacobs WR. The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics. Annu. Rev. Microbiol. 2007;61:35–50. doi: 10.1146/annurev.micro.61.111606.122346. [PubMed] [Cross Ref]
45. Swanson RV, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 2015;59:3042–3051. doi: 10.1128/AAC.00260-15. [PMC free article] [PubMed] [Cross Ref]
46. Newton G, Yun CH, Gennis RB. Analysis of the topology of the cytochrome d terminal oxidase complex of Escherichia coli by alkaline phosphatase fusions. Mol. Microbiol. 1991;5:2511–2518. doi: 10.1111/j.1365-2958.1991.tb02097.x. [PubMed] [Cross Ref]
47. Lenn T, Leake MC, Mullineaux CW. Clustering and dynamics of cytochrome bd-I complexes in the Escherichia coli plasma membrane in vivo. Mol. Microbiol. 2008;70:1397–1407. doi: 10.1111/j.1365-2958.2008.06486.x. [PubMed] [Cross Ref]
48. Kusumoto T, Aoyagi M, Iwai H, Kabashima Y, Sakamoto J. Monitoring enzyme expression of a branched respiratory chain of Corynebacterium glutamicum using an EGFP reporter gene. J. Bioenerg. Biomembr. 2011;43:257–266. doi: 10.1007/s10863-011-9355-6. [PubMed] [Cross Ref]
49. Black PA, et al. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014;58:2491–2503. doi: 10.1128/AAC.02293-13. [PMC free article] [PubMed] [Cross Ref]
50. Lu P, Lill H, Bald D. ATP synthase in mycobacteria: special features and implications for a function as drug target. Biochim. Biophys. Acta. 2014;1837:1208–1218. doi: 10.1016/j.bbabio.2014.01.022. [PubMed] [Cross Ref]
51. Bald D, Villellas C, Lu P, Koul A. Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery. MBio. 2017;8:e00272–17. doi: 10.1128/mBio.00272-17. [PMC free article] [PubMed] [Cross Ref]
52. Cook GM. et al. Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Direction. Microbiol. Spectr. 5, doi:10.1128/microbiolspec.TBTB2-0014-2016doi:10.1128/microbiolspec.TBTB2-0014-2016 (2017). [PMC free article] [PubMed]
53. Balemans W, et al. Novel Antibiotics Targeting Respiratory ATP Synthesis in Gram-positive Pathogenic Bacteria. Antimicro.b Agents Chemother. 2012;56:4131–4139. doi: 10.1128/AAC.00273-12. [PMC free article] [PubMed] [Cross Ref]
54. Schurig-Briccio LA, Yano T, Rubin H, Gennis RB. Characterization of the type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines. Biochim. Biophys. Acta. 2014;1837:954–963. doi: 10.1016/j.bbabio.2014.03.017. [PMC free article] [PubMed] [Cross Ref]
55. Rubin H, et al. Acinetobacter baumannii OxPhos inhibitors as selective antiinfective agents. Bioorg. Med. Chem. Lett. 2015;25:378–383. doi: 10.1016/j.bmcl.2014.11.020. [PubMed] [Cross Ref]
56. Borisov VB, et al. Cytochrome bd oxidase from Escherichia coli displays high catalase activity: An additional defense against oxidative stress. FEBS Lett. 2013;587:2214–2218. doi: 10.1016/j.febslet.2013.05.047. [PubMed] [Cross Ref]
57. Al-Attar S, et al. Cytochrome bd Displays Significant Quinol Peroxidase. Activity. Sci. Rep. 2016;6 doi: 10.1038/srep27631. [PMC free article] [PubMed] [Cross Ref]
58. Feng X, et al. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci USA. 2015;112:7073–7082. doi: 10.1073/pnas.1500791112. [PubMed] [Cross Ref]
59. Yamamoto Y, et al. Respiration metabolism of Group B Streptococcus is activated by environmental haem and quinone and contributes to virulence. Mol. Microbiol. 2005;56:525–534. doi: 10.1111/j.1365-2958.2005.04555.x. [PubMed] [Cross Ref]
60. Hammer ND, et al. Two heme-dependent terminal oxidases power Staphylococcus aureus organ-specific colonization of the vertebrate host. MBio. 2013;4:e00241–13. [PMC free article] [PubMed]
61. Way SS, Sallustio S, Magliozzo RS, Goldberg MB. Impact of either elevated or decreased levels of cytochrome bd expression on Shigella flexneri virulence. J. Bacteriol. 1999;181:1229–1237. [PMC free article] [PubMed]
62. Endley S, McMurray D, Ficht TA. Interruption of the cydB locus in Brucella abortus attenuates intracellular survival and virulence in the mouse model of infection. J. Bacteriol. 2001;183:2454–2462. doi: 10.1128/JB.183.8.2454-2462.2001. [PMC free article] [PubMed] [Cross Ref]
63. Turner AK, et al. Contribution of proton-translocating proteins to the virulence of Salmonella enterica serovars Typhimurium, Gallinarum, and Dublin in chickens and mice. Infect. Immun. 2003;71:3392–3401. doi: 10.1128/IAI.71.6.3392-3401.2003. [PMC free article] [PubMed] [Cross Ref]
64. Jones-Carson J, Husain M, Liu L, Orlicky DJ, Vázquez-Torres A. Cytochrome bd-Dependent Bioenergetics and Antinitrosative Defenses in Salmonella Pathogenesis. MBio. 2016;7:e02052–16. doi: 10.1128/mBio.02052-16. [PMC free article] [PubMed] [Cross Ref]
65. Shepherd M, et al. The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection. Sci. Rep. 2016;6 doi: 10.1038/srep35285. [PMC free article] [PubMed] [Cross Ref]
66. Abdallah AM, et al. A specific secretion system mediates PPE41 transport in pathogenic mycobacteria. Mol. Microbiol. 2006;62:667–679. doi: 10.1111/j.1365-2958.2006.05409.x. [PubMed] [Cross Ref]
67. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 1994;13:908–914. doi: 10.1007/BF02111491. [PubMed] [Cross Ref]
68. van de Weerd R, et al. Inorganic phosphate limitation modulates capsular polysaccharide composition in mycobacteria. J. Biol. Chem. 2016;291:11787–11799. doi: 10.1074/jbc.M116.722454. [PMC free article] [PubMed] [Cross Ref]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group